Results 61 to 70 of about 123,600 (352)

Patient and physician characteristics associated with erythropoiesis-stimulating agent use in patients with myelodysplastic syndromes

Haematologica, 2012
Patient and physician characteristics associated with use of erythropoiesis-stimulating agents in myelodysplastic syndrome patients have not yet been described.
Amy J. Davidoff, Sheila Weiss Smith, Maria R. Baer, Xuehua Ke, Jason M. Bierenbaum, Franklin Hendrick, Diane L. McNally, Steven D. Gore   +7 more
doaj   +1 more source

The Homozygous p.(Arg215Ter) Variant in XRCC2 Is Associated With Atypical Fanconi Anemia Without Major Hematological Abnormalities in Childhood

American Journal of Medical Genetics Part A, EarlyView.
ABSTRACT Fanconi Anemia (FA) is the most frequent inherited bone marrow failure syndrome. A role for the XRCC2 gene in FA was suspected in 2012 and confirmed in 2016, but only two affected individuals have been described thus far, and no long‐term follow‐up is available.
Sabina Cenciarelli, Giulia Bruna Marchetti, Maria Iascone, Maria Grazia Patricelli, Sara Giangiobbe, Gabriella Cinzia Pozzobon, Miriam Nella Savini, Fabio Giglio, Alessandro Aiuti, Paola Carrera, Francesca Ferrua, Angela Peron   +11 more
wiley   +1 more source

Gender effects on cytidine analogue metabolism and myelodysplastic syndrome treatment outcomes [PDF]

, 2012
In vivo, half-lives of cytidine analogues such as 5-azacytidine and decitabine, used to treat myelodysplastic syndromes (MDS), are determined largely by cytidine deaminase (CDA), an enzyme that rapidly metabolizes these drugs into inactive uridine ...
Ania Jankowska, Jaroslaw Maciejewski, Joseph Covey, Kenneth Chan, Kory Engelke, Mikkael Sekeres, Pramod Terse, Quteba Ebrahem, Ramon Tiu, Reda Mahfouz, Tomas Radivoyevitch, Yogen Saunthararajah, Yonghua Ling, Zhenbo Hu   +13 more
core   +1 more source

Zebrafish and CRISPR—A synergistic approach to decipher and cure human diseases

Animal Models and Experimental Medicine, EarlyView.
Zebrafish, with high genetic homology to humans, serves as a powerful vertebrate model for disease modeling and drug discovery. Integration of CRISPR/Cas9 technology enables precise genome editing, facilitating the development of translational models for human diseases.
Manikandan Sivaprakasam, Aashika Raagavi Jeanpierre, Salma Mohammed, Rajesh Srinivasan, Aman Kumar Mohanty   +4 more
wiley   +1 more source

Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial [PDF]

, 2017
Background: Rucaparib, a poly(ADP-ribose) polymerase inhibitor, has anticancer activity in recurrent ovarian carcinoma harbouring a BRCA mutation or high percentage of genome-wide loss of heterozygosity.
Aghajanian, C, Aghajanian, Carol, Amit, A, Armstrong, D K, Armstrong, Deborah K, Banerjee, S N, Birrer, M J, Bologna, A, Buck, M, Buss, M K, Cameron, Terri, Chambers, S K, Chen, L-m, Clamp, A, Clamp, Andrew, Coleman, R L, Coleman, Robert L, Colombo, N, Colombo, Nicoletta, Dean, A, Dean, Andrew, Denys, H, Dirix, L, Drew, Y, El-Balat, A, Elit, L, Floquet, A, Floquet, Anne, Fong, P C, Fong, Peter C, Friedlander, M L, Gabra, H G, Gancedo, M Amenedo, Gancedo, Margarita Amenedo, Garcia-Donas, J, Garcia-Donas, Jesus, Ghatage, P, Giordano, Heidi, Gladieff, L, Goble, Sandra, Goh, J C, Goh, Jeffrey C, Grace, Caroline, Guerra, E M, Harding, Thomas C, Harnett, P, Herraez, A Casado, Holloway, R W, Holloway, Robert W, Hänle, C, Isaacson, Jeff, Jackson, D, Joly, F, Kichenadasse, G, Konecny, G E, Konecny, Gottfried E, Kovel, S, Krabisch, P, Leary, A, Leary, Alexandra, Ledermann, J A, Ledermann, Jonathan A, Leviov, M, Lin, Kevin K, Lortholary, A, Lorusso, D, Lorusso, Domenica, Lotz, J, Ma, L, Maloney, Lara, McNeish, I A, McNeish, Iain A, Medioni, J, Morgan, M A, Morris, R T, Mutch, D G, Neunhöffer, T, O'Donnell, A, O'Malley, D M, O'Malley, David M, Oaknin, A, Oaknin, Ana, Oza, A M, Oza, Amit M, Palacio, I, Parkinson, C, Pignata, S, Plante, M, Powell, M, Provencher, D, Pölcher, M, Raponi, Mitch, Romero, I, Sabbatini, R F, Safra, T, Sanchez, A, Scambia, G, Scambia, Giovanni, Scott, C L, Scott, Clare L, Shapira-Frommer, R, Slomovitz, B M, Stemmer, S, Sun, James, Swisher, E M, Swisher, Elizabeth M, Tamberi, S, Tredan, O, Vanderkwaak, T, Vergote, I, Vulfovich, M, Weberpals, J I, Weberpals, Johanne I, Welch, S, Wimberger, P, You, B, Zamagni, C   +116 more
core   +1 more source

The revolution of myelodysplastic syndromes [PDF]

Therapeutic Advances in Hematology, 2011
Myelodysplastic syndromes (MDS) are clonal disorders of the hematopoietic system with resultant cytopenias and shortened survival. Better recognition of MDS and an aging population, some of whom have been treated with chemotherapy and radiation therapy for other cancers, is largely responsible for the growing incidence of this malignancy, which is ...
Mikkael A, Sekeres, Nelli, Bejanyan
openaire   +2 more sources

Genetic prediction of blood cell reactivity and its potential causal influence on bone continuity and density disorders

Animal Models and Experimental Medicine, EarlyView.
We applied Mendelian randomization to explore causal links between blood cell traits and skeletal disorders. Using genetic instruments from large‐scale summary statistics, we assessed effects on bone continuity, density, and structural integrity. Sensitivity and reverse analyses confirmed robust associations, highlighting potential shared biological ...
Zhiqin Deng, Zhe Zhao, Wenting Jiang, Xiaoqiang Chen, Jianquan Liu, Xu Tao, Zhengyang Lin, Zhenhan Deng, Wencui Li   +8 more
wiley   +1 more source

Presence of new mutations in the TP53 gene in patients with low-risk myelodysplastic syndrome: two case reports

Journal of Medical Case Reports, 2017
Background Myelodysplastic syndromes are heterogeneous disorders. Patients with myelodysplastic syndrome disease often have ineffective hematopoiesis, cytopenias, blood cell dysplasia in one or more cell types, and are at high risk for developing acute ...
Fernando Barroso Duarte, Romélia Pinheiro Gonçalves Lemes, Talyta Ellen de Jesus dos Santos, Maritza Cavalcante Barbosa, João Paulo Leitão de Vasconcelos, Francisco Dário Rocha-Filho, Ilana Zalcberg, Diego Coutinho, Monalisa Feliciano Figueiredo, Luciana Barros Carlos, Paulo Roberto Leitão de Vasconcelos   +10 more
doaj   +1 more source

Long-term outcome after a treosulfan-based conditioning regimen for patients with acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation [PDF]

, 2017
BACKGROUND: Allogeneic hematopoietic cell transplantation (HCT) is a curative therapy for patients with acute myeloid leukemia (AML). However, post-HCT relapse and regimen-related toxicity remain significant barriers to long-term survival.
Al Mumma, Baron, Boztug, Boztug, Bredeson, Burroughs, Carreras, Casper, Casper, Cieri, Copelan, Dalle, Danylesko, Fichtner, Galaup, Glowka, Gupta, Gyurkocza, Kroger, Kroger, Majhail, Meinhardt, Munkelt, Nagler, Nagler, Palmer, Pel, Richardson, Rizzo, Savani, Savani, Scheulen, Schmidmaier, Schmitt, Sengsayadeth, Sengsayadeth, Shimoni, Shimoni, Slatter, ten Brink, Wachowiak, Williams   +41 more
core   +1 more source

USB1 deficiency disrupts neutrophil maturation via RNA dysregulation independent of global pre‐mRNA splicing

Animal Models and Experimental Medicine, EarlyView.
This graphical abstract illustrates the essential role of USB1 in neutrophil maturation. In normal myeloid cells, USB1 acts as an RNA exonuclease, trimming RNA tails to maintain proper RNA network function, which supports the differentiation of myeloid progenitor cells into mature neutrophils.
Hang Li, Guiying Shi, Jiaming Tang, Yiying Huang, Jie Wang, Xuepei Lei, Lin Bai   +6 more
wiley   +1 more source